Collectively, these findings suggest that the NFAT1/IL‐18 signaling pathway is involved in tumor‐induced pain hypersensitivity by regulating neuronal activity through modulation of the NMDA receptor (Figure 8F). This evidence concerns the gene NFATC2 and neoplasm.